Does the media refer more to CRSP or REPL?

In the previous week, Replimune Group had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 14 mentions for Replimune Group and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Replimune Group's score of 0.44 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is REPL or GRFS more profitable?

Grifols has a net margin of 5.54% compared to Replimune Group's net margin of 0.00%. Grifols' return on equity of 6.21% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Grifols 5.54% 6.21% 2.39%

Which has higher earnings & valuation, REPL or PBLS?

Parabilis Medicines has higher revenue and earnings than Replimune Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.15 N/A Parabilis Medicines $148K 30,783.09 N/A N/A N/A

Is REPL or PBLS more profitable?

Parabilis Medicines' return on equity of 0.00% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Parabilis Medicines N/A N/A N/A

Does the media favor REPL or PBLS?

In the previous week, Replimune Group had 11 more articles in the media than Parabilis Medicines. MarketBeat recorded 14 mentions for Replimune Group and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Replimune Group's score of 0.44 indicating that Parabilis Medicines is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to REPL or ACAD?

In the previous week, Replimune Group had 11 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 14 mentions for Replimune Group and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.21 beat Replimune Group's score of 0.44 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, REPL or CELC?

Celcuity is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Replimune Group N/A N/A -$313.94M -$3.15 N/A Celcuity N/A N/A -$177.04M -$4.30 N/A

Is REPL or CELC more profitable?

Replimune Group's return on equity of -159.32% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Replimune Group N/A -159.32% -90.84% Celcuity N/A -350.78% -41.54%

Does the media refer more to REPL or CELC?

In the previous week, Replimune Group had 9 more articles in the media than Celcuity. MarketBeat recorded 14 mentions for Replimune Group and 5 mentions for Celcuity. Celcuity's average media sentiment score of 1.24 beat Replimune Group's score of 0.44 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Replimune Group 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Celcuity 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Replimune Group (REPL) Competitors

$12.92 -0.32 (-2.42%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$12.82 -0.10 (-0.74%)

As of 09/11/2026 07:30 PM Eastern

Compare

REPL vs. CRSP, GRFS, PBLS, ACAD, and CELC

Should you buy Replimune Group stock or one of its competitors? Replimune Group's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Grifols (GRFS), Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), and Celcuity (CELC). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Replimune Group compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Replimune Group (NASDAQ:REPL) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

CRISPR Therapeutics presently has a consensus price target of $68.06, suggesting a potential upside of 31.58%. Replimune Group has a consensus price target of $12.00, suggesting a potential downside of 7.12%. Given CRISPR Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CRISPR Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	6 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.61
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60

Replimune Group has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,424.73	-$581.60M	-$4.76	N/A
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A

CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

In the previous week, Replimune Group had 6 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 14 mentions for Replimune Group and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.85 beat Replimune Group's score of 0.44 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 5.4% of Replimune Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Replimune Group has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
Replimune Group	N/A	-159.32%	-90.84%

Summary

CRISPR Therapeutics beats Replimune Group on 8 of the 15 factors compared between the two stocks.

How does Replimune Group compare to Grifols?

Replimune Group (NASDAQ:REPL) and Grifols (NASDAQ:GRFS) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, Replimune Group had 13 more articles in the media than Grifols. MarketBeat recorded 14 mentions for Replimune Group and 1 mentions for Grifols. Grifols' average media sentiment score of 1.44 beat Replimune Group's score of 0.44 indicating that Grifols is being referred to more favorably in the news media.

Company	Overall Sentiment
Replimune Group	Neutral
Grifols	Positive

Replimune Group has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, Grifols has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Grifols has a net margin of 5.54% compared to Replimune Group's net margin of 0.00%. Grifols' return on equity of 6.21% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Grifols	5.54%	6.21%	2.39%

Replimune Group presently has a consensus price target of $12.00, indicating a potential downside of 7.12%. Grifols has a consensus price target of $10.00, indicating a potential upside of 32.45%. Given Grifols' higher probable upside, analysts plainly believe Grifols is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Grifols	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

92.5% of Replimune Group shares are held by institutional investors. 5.4% of Replimune Group shares are held by insiders. Comparatively, 0.2% of Grifols shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Grifols has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Grifols	$8.51B	0.60	$454.82M	$0.19	39.74

Summary

Grifols beats Replimune Group on 9 of the 16 factors compared between the two stocks.

How does Replimune Group compare to Parabilis Medicines?

Replimune Group (NASDAQ:REPL) and Parabilis Medicines (NASDAQ:PBLS) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

In the previous week, Replimune Group had 11 more articles in the media than Parabilis Medicines. MarketBeat recorded 14 mentions for Replimune Group and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.92 beat Replimune Group's score of 0.44 indicating that Parabilis Medicines is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Replimune Group currently has a consensus target price of $12.00, indicating a potential downside of 7.12%. Parabilis Medicines has a consensus target price of $41.67, indicating a potential upside of 12.98%. Given Parabilis Medicines' stronger consensus rating and higher possible upside, analysts plainly believe Parabilis Medicines is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Parabilis Medicines has higher revenue and earnings than Replimune Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Parabilis Medicines	$148K	30,783.09	N/A	N/A	N/A

Parabilis Medicines' return on equity of 0.00% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Parabilis Medicines	N/A	N/A	N/A

92.5% of Replimune Group shares are held by institutional investors. 5.4% of Replimune Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Parabilis Medicines beats Replimune Group on 6 of the 10 factors compared between the two stocks.

How does Replimune Group compare to ACADIA Pharmaceuticals?

Replimune Group (NASDAQ:REPL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Replimune Group has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market.

Replimune Group presently has a consensus price target of $12.00, suggesting a potential downside of 7.12%. ACADIA Pharmaceuticals has a consensus price target of $34.36, suggesting a potential upside of 23.47%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
ACADIA Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.78

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Replimune Group's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

92.5% of Replimune Group shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 5.4% of Replimune Group shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
ACADIA Pharmaceuticals	$1.07B	4.48	$391M	$2.22	12.54

In the previous week, Replimune Group had 11 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 14 mentions for Replimune Group and 3 mentions for ACADIA Pharmaceuticals. ACADIA Pharmaceuticals' average media sentiment score of 1.21 beat Replimune Group's score of 0.44 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ACADIA Pharmaceuticals beats Replimune Group on 13 of the 16 factors compared between the two stocks.

How does Replimune Group compare to Celcuity?

Replimune Group (NASDAQ:REPL) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation.

Celcuity is trading at a lower price-to-earnings ratio than Replimune Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$313.94M	-$3.15	N/A
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

Replimune Group has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.19, meaning that its stock price is 81% less volatile than the broader market.

Replimune Group's return on equity of -159.32% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-159.32%	-90.84%
Celcuity	N/A	-350.78%	-41.54%

In the previous week, Replimune Group had 9 more articles in the media than Celcuity. MarketBeat recorded 14 mentions for Replimune Group and 5 mentions for Celcuity. Celcuity's average media sentiment score of 1.24 beat Replimune Group's score of 0.44 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	3 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Celcuity	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 5.4% of Replimune Group shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Replimune Group currently has a consensus target price of $12.00, suggesting a potential downside of 7.12%. Celcuity has a consensus target price of $154.55, suggesting a potential upside of 85.20%. Given Celcuity's stronger consensus rating and higher probable upside, analysts clearly believe Celcuity is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.60
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Summary

Replimune Group and Celcuity tied by winning 7 of the 14 factors compared between the two stocks.

Get Replimune Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding REPL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

REPL vs. The Competition

Export

Metric	Replimune Group	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.24B	$3.84B	$7.13B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-4.10	14.25	275.24	25.29
Price / Sales	N/A	1,473.16	656.02	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	6.43	15.12	10.33	6.20
Net Income	-$313.94M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-14.10%	-4.34%	-3.32%	-2.35%
1 Month Performance	-15.22%	-0.02%	-0.41%	-2.77%
1 Year Performance	125.48%	40.64%	19.21%	7.63%

Replimune Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
REPL Replimune Group	1.8396 of 5 stars	$12.92 -2.4%	$12.00 -7.1%	+115.0%	$1.24B	N/A	N/A	210
CRSP CRISPR Therapeutics	2.3557 of 5 stars	$55.61 -1.6%	$68.06 +22.4%	-7.5%	$5.40B	$3.51M	N/A	460	Gap Down
GRFS Grifols	4.762 of 5 stars	$7.82 -0.8%	$10.00 +28.0%	-24.8%	$5.32B	$7.42B	41.13	25,247	Positive News
PBLS Parabilis Medicines	2.6144 of 5 stars	$40.75 flat	$41.67 +2.2%	N/A	$5.03B	N/A	N/A	N/A	Positive News
ACAD ACADIA Pharmaceuticals	4.3742 of 5 stars	$27.87 +0.0%	$34.36 +23.3%	+15.0%	$4.81B	$1.07B	12.56	510	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:REPL) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Replimune Group (REPL) Competitors

REPL vs. CRSP, GRFS, PBLS, ACAD, and CELC

How does Replimune Group compare to CRISPR Therapeutics?

Summary

How does Replimune Group compare to Grifols?

Summary

How does Replimune Group compare to Parabilis Medicines?

Summary

How does Replimune Group compare to ACADIA Pharmaceuticals?

Summary

How does Replimune Group compare to Celcuity?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Replimune Group (REPL) Competitors

REPL vs. CRSP, GRFS, PBLS, ACAD, and CELC

How does Replimune Group compare to CRISPR Therapeutics?

Do analysts recommend CRSP or REPL?

Which has stronger earnings & valuation, CRSP or REPL?

Which has more volatility & risk, CRSP or REPL?

Does the media refer more to CRSP or REPL?

Do institutionals and insiders hold more shares of CRSP or REPL?

Is CRSP or REPL more profitable?

Summary

How does Replimune Group compare to Grifols?

Does the media prefer REPL or GRFS?

Which has more risk and volatility, REPL or GRFS?

Is REPL or GRFS more profitable?

Do analysts rate REPL or GRFS?

Do insiders and institutionals believe in REPL or GRFS?

Which has better earnings and valuation, REPL or GRFS?

Summary

How does Replimune Group compare to Parabilis Medicines?

Does the media favor REPL or PBLS?

Do analysts rate REPL or PBLS?

Which has higher earnings & valuation, REPL or PBLS?

Is REPL or PBLS more profitable?

Do insiders & institutionals believe in REPL or PBLS?

Summary

How does Replimune Group compare to ACADIA Pharmaceuticals?

Which has more risk and volatility, REPL or ACAD?

Do analysts recommend REPL or ACAD?

Is REPL or ACAD more profitable?

Do institutionals & insiders have more ownership in REPL or ACAD?

Which has higher earnings and valuation, REPL or ACAD?

Does the media refer more to REPL or ACAD?

Summary

How does Replimune Group compare to Celcuity?

Which has preferable earnings and valuation, REPL or CELC?

Which has more volatility and risk, REPL or CELC?

Is REPL or CELC more profitable?

Does the media refer more to REPL or CELC?

Do insiders and institutionals have more ownership in REPL or CELC?

Do analysts rate REPL or CELC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

REPL vs. The Competition

Replimune Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools